As part of a series of articles produced in association with Cytel, pharmaphorum’s Richard Staines spoke with Jeremy Rassen, (President and Chief Science Officer at Aetion) about how data obtained from outside the traditional randomized controlled trial setting is transforming drug research.
Read More
Read More